Canvas Dx

by Cognoa  · Based in United States → — Early, Rapid, Equitable Diagnosis of Autism
Family Medicine Pediatrics Psychiatry
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Cognoa is a pediatric behavioral health company that develops digital diagnostic and therapeutic products for children with behavioral health disorders. Its flagship product, Canvas Dx, is the first and only FDA-authorized diagnostic solution designed to equip clinicians to diagnose or rule out Autism Spectrum Disorder (ASD) in children ages 1.5 to 6 years. The tool leverages responsible artificial intelligence to provide an informed, rapid, and universally accessible path to care, aiming to overcome diagnostic delays and inequities. Canvas Dx utilizes a combination of caregiver questionnaires, home video recordings of the child’s behavior, and clinician input, processed by a machine-learning algorithm, to aid in diagnosis.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered diagnostic aid for autism
  • Diagnoses or rules out autism in children ages 1.5 to 6 years
  • Remote, digital evaluation via smartphone app for caregivers
  • Caregiver questionnaires and home video recordings
  • Clinician questionnaire and portal
  • Machine-learning algorithm processes independent inputs
  • Provides positive, negative, or indeterminate diagnosis for ASD
  • Auto-generates detailed developmental reports
  • Supports rapid diagnosis (days, not months or years)
  • Objective, data-driven approach to alleviate biases

Use Cases

  • Early diagnosis of Autism Spectrum Disorder (ASD) in young children
  • Reducing diagnostic delays for autism
  • Equipping primary care clinicians to diagnose autism
  • Overcoming geographical barriers to specialized care
  • Providing objective, data-driven insights to aid clinical judgment
  • Streamlining the path to care and intervention

What Physicians Need to Know

Evidence Base
Canvas Dx is the first and only FDA-authorized diagnostic solution for autism in children ages 1.5 to 6 years, utilizing AI and machine learning. Its foundational research originated at Harvard Medical School, applying machine learning to extensive electronic patient record data. The device is intended as an aid to diagnosis, not a standalone tool, and must be used in conjunction with patient history, clinical observations, and other evidence. It automatically maps concerns to DSM-5 compatible criteria for autism diagnosis.
Clinical Validation Studies
The pivotal study was a prospective, double-blinded, single-arm study across 14 U.S. sites with 425 participants (18-72 months). For determinate outputs, the study reported a sensitivity of 98.4%, specificity of 78.9%, PPV of 80.8%, and NPV of 98.3%. Initial pivotal study results showed 68% of participants received an 'indeterminate' result, which was later reduced to 33.5% (66.5% determinate rate) with an optimized algorithm without significant accuracy changes. Real-world data analysis (254 prescriptions) demonstrated a determinate rate of 62.99%, with an NPV of 97.56% and PPV of 92.44%, and showed children received a positive diagnosis over a year earlier than the current median age. The tool exhibits equitable performance across diverse demographics.
Alert Fatigue Management
Canvas Dx is designed to mitigate alert fatigue by providing three distinct outputs: 'positive for autism,' 'negative for autism,' or 'indeterminate.' The system deliberately abstains from making a diagnostic prediction when there is insufficient information, returning an 'indeterminate' result, which is considered an important safety mechanism.
Differential Diagnosis Support
The tool provides a detailed report outlining developmental strengths and concerns, which assists in making informed decisions for all children, including those requiring further assessment. For 'indeterminate' results, the system suggests continued monitoring or additional evaluation for autism and/or non-autism conditions. It is not intended for use in patients with specific conditions that were excluded from clinical studies, such as known deafness, blindness, major dysmorphic features, genetic conditions (e.g., Rett syndrome, Fragile X), or epilepsy.
Guideline Update Frequency
The AI/machine learning algorithm of Canvas Dx is designed for optimization through training on new data, with post-FDA authorization algorithmic optimization and real-world performance continuously tracked. An algorithm update has already demonstrated a reduction in indeterminate results. Due to rapid neurodevelopmental changes, device evaluation should be completed within 60 days of prescription.
Clinical Workflow Integration
Canvas Dx is designed for integration into both primary care and specialist settings. The workflow involves a clinician completing a 10-minute questionnaire via a web portal, while caregivers use a smartphone app to answer questions and upload two short home videos. The AI then processes this data to generate a diagnostic prediction and a detailed child development report, accessible to the clinician via email notification and the web portal. It offers automated documentation features, mapping concerns to DSM-5 criteria, and built-in report creation. No special training or certification is required for clinicians to use the tool. It is a prescription-only device. The clinician portal supports Chrome and Safari on Mac/Windows, and the app is compatible with iOS and Android.
Decision Audit Trail
The system generates a 'Detailed Report' that captures the child's developmental strengths and challenges, including a visual summary and caregiver/HCP-identified concerns mapped to DSM-5 compatible domains. Clinicians have access to their own questionnaire responses, caregiver responses, uploaded videos, and device performance metrics to support their clinical judgment. These reports can be downloaded as PDFs, which contain personal health information.
Physician Tip

Canvas Dx serves as a valuable adjunct, not a replacement, for clinical judgment in diagnosing autism. Leverage the detailed reports and remote data collection (caregiver videos) to gain comprehensive insights into a child's behavior in their natural environment, which can be challenging to observe in a clinical setting. Be prepared to interpret 'indeterminate' results as a signal for further specialist evaluation or continued monitoring. The tool aims to significantly shorten the diagnostic pathway, enabling earlier intervention during a critical neurodevelopmental window.

Canvas Dx integrates into clinical workflows via a web portal for healthcare providers and a smartphone app for caregivers. It supports e-prescribing through various Electronic Medical Record (EMR) systems, including AllScripts, Cerner, eClinicalWorks, Epic, IMS, and Practice Fusion. Cognoa provides a dedicated customer service team, 'Cognoa Connect,' to assist both clinicians and families with product support and usage.

Details

Category Clinical Decision Support & Reference, Mental & Behavioral Health AI
Pricing Contact for pricing
  • Reimbursed by some insurers (e.g., Highmark, Medicaid); accepts HSA, FSA, and cash payments for Cognoa Clinical services
DeploymentCloud-based (online portals and smartphone application)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Canvas Dx received FDA marketing authorization via De Novo classification request (DEN200069) in June 2021 as a Pediatric Autism Spectrum Disorder diagnosis aid. It is a prescription device (Rx only) intended as an aid in the diagnosis of ASD for patients 18 months through 72 months (1.5 to 6 years), not as a stand-alone diagnostic device. The K number K243558 is associated with this device, with a date of 04/11/2025, likely indicating a renewal or updated listing.
Integrations
EHR Not specified
Specialties Family Medicine, Pediatrics, Psychiatry

What the Web Says

Canvas Dx is an AI-powered diagnostic device for autism spectrum disorder (ASD) in children aged 18 months to 6 years. It is the first FDA-authorized device of its kind, designed to aid in earlier diagnosis by providing a risk assessment based on video analysis of a child's behavior and parent-reported information. Reviews highlight its potential to reduce diagnostic delays and improve access to care, particularly in underserved areas.

Overall: Positive

Strengths

  • First FDA-authorized AI-powered diagnostic for ASD, lending credibility and regulatory approval.
  • Potential for earlier diagnosis of ASD, which can lead to earlier intervention and improved outcomes.
  • Utilizes objective measures (video analysis) alongside parent input, potentially reducing subjective bias.
  • Can be used in primary care settings, potentially increasing access to diagnostic services and reducing the burden on specialists.
  • Aims to reduce long wait times for traditional ASD diagnostic evaluations.
  • Non-invasive and relatively easy to administer compared to traditional diagnostic processes.

Limitations

  • Relatively new technology, so long-term efficacy and real-world impact are still being observed.
  • Requires internet access and a smartphone/tablet for video recording and data submission, which could be a barrier for some.
  • As an aid, it does not replace a clinical diagnosis by a specialist, requiring further steps for confirmation.
  • Concerns about potential over-diagnosis or misdiagnosis if not used appropriately or if clinicians over-rely on the AI.
  • Data privacy and security concerns related to submitting sensitive video and health information.
  • Cost and insurance coverage may be a barrier for some patients or healthcare providers.

Based on reviews from: FDA, Cognoa Official Website, Healthcare IT News, MedTech Dive, Pediatrics (Journal), Reddit (various subreddits discussing AI in healthcare)

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Canvas Dx

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Fierce Biotech
Cognoa Receives FDA Marketing Authorization for First-of-its-kind Autism Diagnosis Aid
Cognoa's Canvas Dx, an AI-powered app, received FDA marketing authorization in June 2021, making it the first such device to help primary care physicians diagnose autism in children aged 18 months to five years. The device aims to address the crisis of late diagnoses and disparities in access to care.
2021-06
CHOC (Children's Hospital of Orange County)
CHOC doctors lead study that helps garner FDA authorization for novel autism diagnostic device
CHOC doctors played a key role in the study that led to FDA authorization for Canvas Dx, an AI-powered diagnostic aid for autism. The device helps primary care physicians make data-informed clinical decisions for children at risk of developmental delay, potentially reducing the need for specialist referrals by at least 30%.
2021-08
npj Digital Medicine
Evaluation of an Artificial Intelligence-Based Medical Device for Diagnosis of Autism Spectrum Disorder
Cognoa announced in May 2022 that npj Digital Medicine published data from its pivotal study of Canvas Dx, an AI-based diagnosis aid for autism spectrum disorder. The study demonstrated strong agreement between Canvas Dx outputs and specialist diagnoses, with high accuracy in identifying children with and without ASD.
2022-05
Fierce Healthcare
Cognoa's FDA-approved autism diagnostic tool now in network for Highmark members
In January 2024, Cognoa announced Highmark as its first commercial payer partner for Canvas Dx, making the FDA-approved autism diagnostic tool reimbursed for Highmark members. This partnership aims to provide earlier and more equitable access to diagnosis for children.
2024-01
PR Newswire
Cognoa Advocates for Expanded Insurance Coverage of Canvas Dx as CDC Reports 1 in 31 Children Now Identified with Autism
Cognoa issued a press release in April 2025, urging expanded insurance coverage for Canvas Dx in response to new CDC data showing 1 in 31 U.S. children are identified with autism. The company emphasizes the need for equitable access to early diagnosis.
2025-04
PMC (PubMed Central)
Integration of an Artificial Intelligenceu2013Based Autism Diagnostic Device into the ECHO Autism Primary Care Workflow: Prospective Observational Study
A prospective observational study published in October 2025 explored the integration of Canvas Dx into the ECHO Autism Primary Care workflow. The study found that using Canvas Dx significantly reduced the time from initial clinician concern to autism diagnosis, averaging 39.22 days compared to 180-264 day waits at specialist centers.
2025-10
Breaking News ABA
AI Autism Screening Tools: Three Startups, One FDA Question, and a Lot of Families Hoping
An article from March 2026 discusses Canvas Dx as the first AI-powered autism diagnostic tool to receive De Novo authorization from the FDA, establishing a new regulatory classification. It highlights the system's three-component assessment model and its potential to move autism identification to primary care.
2026-03
Charity Journal
Catalight and Cognoa partner to cut autism diagnosis wait time from years to days
In April 2026, Catalight Group and Cognoa partnered to create an end-to-end autism care pathway, utilizing Canvas Dx to shorten diagnosis times from years to days. This collaboration aims to address the fragmented path from diagnosis to comprehensive care.
2026-04

Videos

Product demos, reviews, and walkthroughs for Canvas Dx.

View all on YouTube

No FAQs available yet for this tool.

Related Tools

Cortex
Cortex
Clinical Decision Support & Reference
Cortex Workspace is a secure, HIPAA-compliant AI platform designed to streamline healthcare workflows and enhance decision-making for physicians.
Starts free, then $29/month for individual plan (save 10% annually). other plans: enthusiast ($99/month), business ($349/month), enterprise (contact sales).
SureMediks ProView
SureMediks (Rasimo Systems, LLC)
Clinical Decision Support & Reference
SureMediks is an AI-powered clinical decision support and metabolic health platform that automates care workflows for specialists, providing AI-generated patient summaries, automated chart review, and real-time biometric alerts.
SOAP Health
SOAP Health
Clinical Decision Support & Reference
SOAP Health is a Florida-based startup transforming patient intake with AI-powered diagnosis, offering a comprehensive solution that improves diagnosis accuracy and empowers patients and physicians.
Oxipit ChestLink
Oxipit (part of Sectra group)
Clinical Decision Support & Reference
Oxipit ChestLink is the world's first CE Class IIb-certified autonomous AI application for healthy chest X-ray reporting, capable of identifying normal studies with 99.9% sensitivity. It automates the reporting of normal chest X-rays, reducing radiologist workload and improving efficiency.
KATE AI
Mednition
Clinical Decision Support & Reference
KATE AI is a nurse-built clinical decision support tool for emergency departments that analyzes incoming patients in real-time to flag high-risk cases that standard acuity scoring might miss. It has supported over 5,000,000 patient visits, helping emergency teams deliver safer, faster, and more informed care.
Fee-based, not publicly disclosed.
MCG Health
MCG Health
Clinical Decision Support & Reference
MCG Health provides industry-leading evidence-based guidance and technologies to optimize health outcomes, drive operational efficiency, and achieve cost savings. Their solutions are utilized by thousands of hospitals, a majority of U.S. health plans, and various government health programs.
Contact for pricing

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.